First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis

BackgroundThe aim of the present study was to evaluate the cost-effectiveness of durvalumab plus platinum–etoposide versus platinum–etoposide as first-line treatments for small-cell lung cancer from the perspective of the US payer.MethodsThis study established a partition survival model for three he...

Full description

Bibliographic Details
Main Authors: Longfeng Zhang, Yongfu Hang, Maobai Liu, Na Li, Hongfu Cai
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Oncology
Subjects:
durvalumab
platinum–etoposide
cost-effectiveness
extensive-stage small-cell lung cancer
small cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.602185/full

Similar Items

Similar Items